Cargando…

Revisiting anti-angiogenic therapy for recurrent glioblastoma

Detalles Bibliográficos
Autor principal:	Peters, Katherine B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799277/ https://www.ncbi.nlm.nih.gov/pubmed/35117133 http://dx.doi.org/10.21037/tcr.2019.05.25

Ejemplares similares

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)

Anti-angiogenic therapies in the management of glioblastoma
por: Schulte, Jessica D., et al.
Publicado: (2021)

Imatinib may be ABL to improve anti-angiogenic therapy
por: Raimondi, Claudio, et al.
Publicado: (2015)

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
por: Talati, Pratik, et al.
Publicado: (2021)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
por: Plate, Karl H., et al.
Publicado: (2012)

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022)

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma
por: Castelli, Chiara, et al.
Publicado: (2013)

Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
por: Zhang, Ashley B., et al.
Publicado: (2023)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Recurrent Glioblastoma: Nuances and Insights
por: Alimohamadi, Maysam, et al.
Publicado: (2021)

Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy
por: Kwiatkowski, Sam C., et al.
Publicado: (2017)

Sales for anti-angiogenic drugs
por: Ribatti, Domenico
Publicado: (2017)

Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance
por: Buccarelli, Mariachiara, et al.
Publicado: (2022)

Reactive resistance to anti-angiogenic drugs
por: Bousquet, Guilhem, et al.
Publicado: (2015)

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma
por: Obad, Nina, et al.
Publicado: (2017)

Revisiting regulatory T cells for stroke therapy
por: Lee, Juneyoung, et al.
Publicado: (2022)

A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition
por: Labanca, Valentina, et al.
Publicado: (2016)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?
por: Hochster, H S
Publicado: (2013)

Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma
por: Guarnaccia, Laura, et al.
Publicado: (2021)

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
por: Verhoeff, Joost JC, et al.
Publicado: (2009)

Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
por: Jeon, Hanwool, et al.
Publicado: (2023)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Deregulation of the circadian clock machinery: A novel biomarker for anti-angiogenic drug resistance in colorectal cancer
por: Della-Morte, David
Publicado: (2019)

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Revisiting the Concept of the Edited Collection: Bioinformational Philosophy and Postdigital Knowledge Ecologies
por: Peters, Michael A., et al.
Publicado: (2021)

Using proteomimetics to switch angiogenic signaling
por: Teng, Peng, et al.
Publicado: (2022)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance
por: Moon, Peter Kim, et al.
Publicado: (2019)

Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery
por: Eze, Chukwuka, et al.
Publicado: (2020)

Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma
por: Angara, Kartik, et al.
Publicado: (2017)

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme
por: Zheng, Shuhua, et al.
Publicado: (2021)

Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
por: Joshkon, Ahmad, et al.
Publicado: (2022)

Antithrombin in sepsis revisited
por: Levi, Marcel
Publicado: (2005)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Revisiting the revisit: added evidence for a social chemosignal in human emotional tears
por: Sobel, Noam
Publicado: (2017)

Therapeutic Injury and Tumor Regrowth: Tumor Resection and Radiation Establish the Recurrent Glioblastoma Microenvironment
por: Silver, Daniel J., et al.
Publicado: (2018)

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)
por: Demeure, Kevin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3gm2o72hv1s41vjurc3g6442ii